KNIGHT THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.73 CAD | +0.70% |
|
+0.17% | +10.40% |
| 22/03 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
| 21/03 | Knight Therapeutics Reports Fourth Quarter Results | MT |
Evolution of the average Target Price on Knight Therapeutics Inc.
Price target over the last 5 years
History of analyst recommendation changes
b673942d84156.TLQlAKkU2iiBJzACjcUdCl90LPPjI-x8PksejqEpbTM.JcETaJ8hvEasSGZw7Ih_bj4Se8fbF5ZLfCgz1uxEP0sChh05wiaYZdhUXw~a2aae428c1f563ce576c909f6e8c71d7
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.73
CAD
Average target price
6.729
CAD
Spread / Average Target
+17.43%
High Price Target
7.6
CAD
Spread / Highest target
+32.64%
Low Price Target
5.25
CAD
Spread / Lowest Target
-8.38%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Knight Therapeutics Inc.
| RBC Capital Markets | |
| National Bank | |
| Stifel GMP |
Trading Rating
Investor Rating
ESG Refinitiv
D+
EPS Revisions
- Stock Market
- Equities
- GUD Stock
- Consensus Knight Therapeutics Inc.
